Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease

View ORCID ProfileDavid M Cash, Katy E Morgan, Antoinette O’Connor, Thomas D Veale, View ORCID ProfileIan B Malone, Teresa Poole, View ORCID ProfileTammie LS Benzinger, View ORCID ProfileBrian A Gordon, View ORCID ProfileLaura Ibanez, Yan Li, Jorge J. Llibre-Guerra, Eric McDade, Guoqiao Wang, View ORCID ProfileJasmeer P Chhatwal, View ORCID ProfileGregory S Day, Edward Huey, View ORCID ProfileMathias Jucker, Johannes Levin, Yoshiki Niimi, James M Noble, Jee Hoon Roh, Racquel Sánchez-Valle, View ORCID ProfilePeter R Schofield, View ORCID ProfileRandall J Bateman, Chris Frost, Nick C Fox, The Dominantly Inherited Alzheimer Network (DIAN)
doi: https://doi.org/10.1101/2024.11.12.24316919
David M Cash
1Dementia Research Centre, UCL Queen Square Institute of Neurology, First floor, 8-11 Queen Square, London, WC1N 3AR, UK
2UK Dementia Research Institute, 6th Floor, Maple House, Tottenham Court Road, London W1T 7NF, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David M Cash
  • For correspondence: d.cash{at}ucl.ac.uk
Katy E Morgan
3London School of Hygiene and Tropical Medicine, Keppel Street London, WC1E 7HT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoinette O’Connor
1Dementia Research Centre, UCL Queen Square Institute of Neurology, First floor, 8-11 Queen Square, London, WC1N 3AR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas D Veale
1Dementia Research Centre, UCL Queen Square Institute of Neurology, First floor, 8-11 Queen Square, London, WC1N 3AR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian B Malone
1Dementia Research Centre, UCL Queen Square Institute of Neurology, First floor, 8-11 Queen Square, London, WC1N 3AR, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ian B Malone
Teresa Poole
3London School of Hygiene and Tropical Medicine, Keppel Street London, WC1E 7HT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tammie LS Benzinger
4Department of Radiology. Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tammie LS Benzinger
Brian A Gordon
4Department of Radiology. Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110 USA
5Knight Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Ave., Suite 200, St. Louis, MO 63108 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian A Gordon
Laura Ibanez
6Department of Neurology, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
7Department of Psychiarty, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura Ibanez
Yan Li
6Department of Neurology, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge J. Llibre-Guerra
6Department of Neurology, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric McDade
6Department of Neurology, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guoqiao Wang
6Department of Neurology, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jasmeer P Chhatwal
8Brigham and Women’s Hospital; Massachusetts General Hospital; Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jasmeer P Chhatwal
Gregory S Day
9Department of Neurology, Mayo Clinic, 4500 San Pablo Rd S, Jacksonville, FL 32224, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gregory S Day
Edward Huey
10Alpert Medical School of Brown University, Department of Psychiatry and Human Behavior, 222 Richmond St., Providence, RI 02903, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Jucker
11Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Straße 3, 72076 Tübingen, Germany
12German Center for Neurodegenerative Diseases (DZNE), Otfried-Müller-Straße 23, 72076 Tübingen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathias Jucker
Johannes Levin
13Department of Neurology, LMU University Hospital, Marchioninistr. 15 D-81377, Munich, Germany
14German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17,81377 Munich, Germany
15Munich Cluster for Systems Neurology (SyNergy), Feodor-Lynen-Str. 17, 81377 Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiki Niimi
16Unit for early and exploratory clinical development, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M Noble
17Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, GH Sergievksy Center, Columbia University, 710 W 168th St #3, New York, NY 10032, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jee Hoon Roh
18Departments of Neurology and Physiology, Korea University Anam Hospital, Korea University College of Medicine, 73 goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic Of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Racquel Sánchez-Valle
19Alzheimer’s disease and other cognitive disorders group. Hospital Clínic de Barcelona. FRCB-IDIBAPS. University of Barcelona, Carrer de Villarroel, 170, L’Eixample, 08036 Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter R Schofield
20Neuroscience Research Australia, Margarete Ainsworth Building Barker Street, Randwick NSW 2031 Australia
21School of Biomedical Sciences, University of New South Wales, UNSW Sydney, NSW 2052 Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter R Schofield
Randall J Bateman
5Knight Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Ave., Suite 200, St. Louis, MO 63108 USA
6Department of Neurology, Washington University in St Louis, 660 S. Euclid Ave., St. Louis, MO 63110 USA
22Hope Center for Neurological Disorders, Washington University in St Louis, 4370 Duncan Ave., St. Louis, MO 63110, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Randall J Bateman
Chris Frost
3London School of Hygiene and Tropical Medicine, Keppel Street London, WC1E 7HT, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick C Fox
1Dementia Research Centre, UCL Queen Square Institute of Neurology, First floor, 8-11 Queen Square, London, WC1N 3AR, UK
2UK Dementia Research Institute, 6th Floor, Maple House, Tottenham Court Road, London W1T 7NF, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

INTRODUCTION Alzheimer disease (AD)-modifying therapies are approved for treatment of early-symptomatic AD. Autosomal dominant AD (ADAD) provides a unique opportunity to test therapies in presymptomatic individuals.

METHODS Using data from the Dominantly Inherited Alzheimer Network (DIAN), sample sizes for clinical trials were estimated for various cognitive, imaging, and CSF outcomes. Sample sizes were computed for detecting a reduction of either absolute levels of AD-related pathology (amyloid, tau) or change over time in neurodegeneration (atrophy, hypometabolism, cognitive change).

RESULTS Biomarkers measuring amyloid and tau pathology had required sample sizes below 200 participants per arm (examples CSF Aβ42/40: 47[95%CI 25,104], cortical PIB 49[28,99], CSF p-tau181 74[48,125]) for a four-year trial in presymptomatic individuals (CDR=0) to have 80% power (5% statistical significance) to detect a 25% reduction in absolute levels of pathology, allowing 40% dropout. For cognitive, MRI, and FDG, it was more appropriate to detect a 50% reduction in rate of change. Sample sizes ranged from 250-900 (examples hippocampal volume: 338[131,2096], cognitive composite: 326[157,1074]). MRI, FDG and cognitive outcomes had lower sample sizes when including indivduals with mild impairment (CDR=0.5 and 1) as well as presymptomatic individuals (CDR=0).

DISCUSSION Despite the rarity of ADAD, presymptomatic clinical trials with feasible sample sizes given the number of cases appear possible.

Competing Interest Statement

DMC reports consultancy fees for Perceptive Imaging. JJLG is supported by NIH-NIA (K01AG073526), the Alzheimers Association (AARFD-21-851415, SG-20-690363), the Michael J. Fox Foundation (MJFF-020770), the Foundation for Barnes Jewish Hospital and the McDonnell Academy. EMD received support from the National Institute on Aging, an anonymous organization, the GHR Foundation, the DIAN-TU Pharma Consortium, Eli Lilly, and F Hoffmann La-Roche; has received speaking fees from Eisai and Eli Lilly; and is on the data safety and monitoring board and advisory boards of Eli Lilly, Alector, and Alzamend. GD reports no competing interests directly relevant to this work. His research is supported by NIH (K23AG064029, U01AG057195, U01NS120901, U19AG032438). He serves as a consultant for Parabon Nanolabs Inc and as a Topic Editor (Dementia) for DynaMed (EBSCO). He is the co-Project PI for a clinical trial in anti-NMDAR encephalitis, which receives support from NINDS (U01NS120901) and Amgen Pharmaceuticals; and a consultant for Arialys Therapeutics. He has developed educational materials for Continuing Education Inc and Ionis Pharmaceutical. He owns stock in ANI pharmaceuticals. Dr. Day's institution has received support from Eli Lilly for development and participation in an educational event promoting early diagnosis of symptomatic Alzheimer disease, and in-kind contributions of radiotracer precursors for tau-PET neuroimaging in studies of memory and aging (via Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly). PRS receives funding from the National Health and Medical Research Council (Australia) grants 1176716 and 2022057 and the Medical Research Future Fund (Australia) grants 1200428 and 1200428. He is a director (unpaid) of the Australian Dementia Network Ltd. RJB, Professor of Neurology at Washington University School of Medicine (WUSM) receives lab research funding from the National Institutes of Health, Alzheimers Association, BrightFocus Foundation, Rainwater Foundation, Association for Frontotemporal Degeneration FTD Biomarkers Initiative, Tau Consortium, Novartis, Centene Corporation, Association for Frontotemporal Degeneration, the Cure Alzheimers Fund, Coins for Alzheimers Research Trust Fund, The Foundation for Barnes-Jewish Hospital, Good Ventures Foundation, DIAN-TU Pharma Consortium, Centene Corporation, Tau SILK Consortium (AbbVie, Biogen, Eli Lilly and Company and an anonymous organization), the NfL Consortium (AbbVie, Biogen, Bristol Meyers Squibb, Hoffman La Roche, and an anonymous organization). RJB has received honoraria as a speaker/consultant/advisory board member from Eisai, F. Hoffman-LaRoche, Janssen, Biogen; and reimbursement of travel expenses from Korean Dementia Association, American Neurological Association, Fondazione Prada, Weill Cornell Medical College, Harvard University, CTAD, FBRI, Beeson Foundation, Adler, Alzheimers Association Roundtable, Duke Margolis Roundtable, Bright Focus Foundation, Tau Consortium Investigators, NAPA Advisory Council on Alzheimers Research. RJB serves as principal investigator of the DIAN-TU, which is supported by the Alzheimers Association, GHR Foundation, an anonymous organization and the DIAN-TU Pharma Consortium (Active: Biogen, Eisai, Eli Lilly and Company/Avid Radiopharmaceuticals, F. Hoffman-La Roche/Genentech, and Janssen. Previous: Abbvie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi, and United Neuroscience). The DIAN-TU-001 Clinical Trial is supported by Pharmaceutical Partners Eli Lilly and Company, F. Hoffman-La Roche and Janssen, the Alzheimers Association, NIH U01AG042791, NIH U01AG42791-S1 (FNIH and Accelerating Medicines Partnership), NIH R01AG046179, NIH R56AG053267, NIH R01AG053267, NIH U01AG059798, NIH R01AG068319, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState, Cerveau, Signant Health and Eisai Corporation. RJB is a co-founder of C2N Diagnostics and receives income from C2N Diagnostics for serving on the scientific advisory board. Washington University (WU) has equity ownership interest in C2N Diagnostics. C2N Diagnostics will be analyzing samples from the Knight Family DIAN-TU-001 trial of E2814 for primary, secondary, and exploratory endpoints. Should the DIAN-TU trials impact the value of C2N Diagnostics, WU and RJB could directly benefit. NCF reports consulting fees from Biogen, Eisai, Ionis, Lilly, Roche/Genentech, and Siemens paid to UCL; he has served on a Data Safety Monitoring Board for Biogen; he acknowledges grant support from the Alzheimers Society, Alzheimers Research UK, Rosetrees Trust, the Sigrid Rausing Trust, the UK Dementia Research Institute and the UK NIHR UCLH Biomedical Research Centre. Johannes Levin reports speaker fees from Bayer Vital, Biogen, EISAI, TEVA, Zambon, Esteve, Merck and Roche, consulting fees from Axon Neuroscience, EISAI and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers and is inventor in a patent "Oral Phenylbutyrate for Treatment of Human 4-Repeat Tauopathies" (EP 23 156 122.6) filed by LMU Munich. In addition, he reports compensation for serving as chief medical officer for MODAG GmbH, is beneficiary of the phantom share program of MODAG GmbH and is inventor in a patent "Pharmaceutical Composition and Methods of Use" (EP 22 159 408.8) filed by MODAG GmbH, all activities outside the submitted work. All other authors have no competing interests to disclose.

Funding Statement

Data collection and sharing for this project was supported by The Dominantly Inherited Alzheimer's Network (DIAN, U19AG032438) funded by the National Institute on Aging (NIA), the German Center for Neurodegenerative Diseases (DZNE), Raul Carrea Institute for Neurological Research (FLENI), Partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, AMED, the Korea Dementia Research Project through the Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (HU21C0066) and the Instituto de Salud Carlos III, Spain (grant number 20/00448 to RSV). DMC work is supported by the Alzheimer's Society(AS‐PG‐15-025), UK Dementia Research Institute which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK, Alzheimer's Association (SG-666374-UK BIRTH COHORT) and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre KEM was supported by an MRC skills development fellowship MR/P014372/1.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board (IRB) of Washington University School of Medicine in St. Louis approved the study with the IRB ID# 201106339, and research was performed in accordance with the approved protocols The Ethics Committee of University College London (South Central-Berkshire ethics committe) gave ethics approval for this work under reference 09/HA0505/73.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • ↵* Joint first authors

  • ↵† Joint senior authors

  • This revision addresses various elements picked up in peer review and places a focus on the presymptomatic trial design with the DIAN-TU-001 eligibility crieteria as a benchmark

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

https://dian.wustl.edu/our-research/for-investigators/dian-observational-study-investigator-resources/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 07, 2025.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease
David M Cash, Katy E Morgan, Antoinette O’Connor, Thomas D Veale, Ian B Malone, Teresa Poole, Tammie LS Benzinger, Brian A Gordon, Laura Ibanez, Yan Li, Jorge J. Llibre-Guerra, Eric McDade, Guoqiao Wang, Jasmeer P Chhatwal, Gregory S Day, Edward Huey, Mathias Jucker, Johannes Levin, Yoshiki Niimi, James M Noble, Jee Hoon Roh, Racquel Sánchez-Valle, Peter R Schofield, Randall J Bateman, Chris Frost, Nick C Fox, The Dominantly Inherited Alzheimer Network (DIAN)
medRxiv 2024.11.12.24316919; doi: https://doi.org/10.1101/2024.11.12.24316919
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer’s disease
David M Cash, Katy E Morgan, Antoinette O’Connor, Thomas D Veale, Ian B Malone, Teresa Poole, Tammie LS Benzinger, Brian A Gordon, Laura Ibanez, Yan Li, Jorge J. Llibre-Guerra, Eric McDade, Guoqiao Wang, Jasmeer P Chhatwal, Gregory S Day, Edward Huey, Mathias Jucker, Johannes Levin, Yoshiki Niimi, James M Noble, Jee Hoon Roh, Racquel Sánchez-Valle, Peter R Schofield, Randall J Bateman, Chris Frost, Nick C Fox, The Dominantly Inherited Alzheimer Network (DIAN)
medRxiv 2024.11.12.24316919; doi: https://doi.org/10.1101/2024.11.12.24316919

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3284)
  • Dentistry and Oral Medicine (362)
  • Dermatology (276)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1168)
  • Epidemiology (13346)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5138)
  • Geriatric Medicine (480)
  • Health Economics (781)
  • Health Informatics (3260)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (428)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14617)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4909)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4198)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (479)
  • Sexual and Reproductive Health (496)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (203)